

REMARKS

Claims 1, 6, 33, 47-54, and 56-62 were pending prior to entry of the present amendment. The claims as currently pending are included above, although no amendments are made to the claims in this submission.

A Request for Continued Examination is filed herewith to allow the consideration of the accompanying Information Disclosure Statement.

Applicants address each of the objections and rejections in the order in which they appear in the Action.

I. Objection to Drawings Addressed

The Action indicates that corrected drawings must be submitted. The description of Figures 41a and 41b has been added to the Specification. In addition, a New Sheet of drawings depicting Figures 41a and 41b has been added as page 22 of the Figures, and Replacement Sheets of pages 1-21 that reflect the addition of the New Sheet have been provided herein in response to the points raised by the Examiner during the March 29, 2010 telephonic interview.

II. Conclusion

All claim rejections being addressed in full, Applicants respectfully requests consideration of the attached IDS, indicated by return of an initialed Form 1449, and withdrawal of any outstanding objection or rejection, and the issuance of a Notice of Allowance. Should the Examiner have any questions regarding the foregoing, Applicants respectfully request that the Examiner contact the undersigned, who can be reached at (919) 483-8022.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicant
Reg. No. 39,009

Date: 2010-July-19
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988